FMR1 and fragile X-associated tremor/ataxia syndrome: Thus, determining the appropriate dose of ASO–CCG to ensure both the preservation of sufficient FMRP levels and a beneficial reduction in the pathogenic processes causing FXTAS should be the goal of future studies.